Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: Rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) are common disorders associated with increased rates of cardiovascular disease (CVD), but the contribution of cytokine-induced inflammation to impaired cardiovascular function in these conditions remains poorly understood. OBJECTIVES: We assessed the effect of anti-TNF therapy on myocardial and vascular function, myocardial tissue characteristics and perfusion in inflammatory arthropathy and systemic rheumatic disease (IASRD) patients, using cardiovascular magnetic resonance (CMR). METHODS: 20 RA patients, 7 AS patients, 5 PsA patients without previously known CVD scheduled to commence anti-TNF therapy and 8 RA patients on standard disease modifying antirheumatic drugs underwent CMR at 1.5 T, including cine, tagging, pulse wave velocity (PWV), T2-weighted, native and postcontrast T1 mapping, ECV quantification, rest and stress perfusion and late gadolinium enhancement (LGE) imaging. RESULTS: Following anti-TNF therapy, there was significant reversal of baseline subclinical cardiovascular dysfunction, as evidenced by improvement in peak systolic circumferential strain (p 

Original publication

DOI

10.1016/j.ijcard.2018.06.099

Type

Journal article

Journal

Int J Cardiol

Publication Date

01/11/2018

Volume

270

Pages

253 - 259

Keywords

Ankylosing spondylitis, Cardiovascular magnetic resonance, Diffuse myocardial fibrosis, Extracellular volume estimation, Inflammation, Late gadolinium enhancement, Psoriatic arthritis, Rheumatoid arthritis, T1 time, Adult, Anti-Inflammatory Agents, Non-Steroidal, Antirheumatic Agents, Cohort Studies, Electrocardiography, Female, Humans, Male, Middle Aged, Myocarditis, Prospective Studies, Rheumatic Heart Disease, Tumor Necrosis Factor-alpha